AbbVie agreed to license up to $2.54 billion of bispecific programs from DISCO Pharmaceuticals, once DISCO completes specified research activities. The pact gives AbbVie an option to exclusively license selected programs for further development, adding to AbbVie’s recent streak of dealmaking in oncology. DISCO’s approach is built around AND-gated bispecific antibodies designed to bind with high avidity only when two target antigens are co-expressed on the same tumor cell. DISCO says the design aims to expand addressable target pairs while reducing on-target, off-tumor toxicity, a recurring challenge in solid-tumor bispecific development. The company’s surfaceome mapping platform (DISCOtech) identifies cancer-specific target pairs, and the collaboration follows DISCO’s earlier licensing deal with Amgen (up to $618 million). For AbbVie, the new agreement further deepens its external innovation strategy at a time when the company is also pursuing acquisitions and other partnering moves.
Get the Daily Brief